Avalo Therapeutics, Inc.
- AVTX
- NASDAQ
- Biotechnology
- Immunology Therapeutics
- Immuno-Oncology
- Rare Genetic Disease Drugs
$11.47
Today +1.82%Quote Oct 19, 2026, 04:10 PM UTC
−32.47%over the last month
Max drawdown −32.5%From 1-month high −32.5%3 months −38.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Avalo Therapeutics
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
33
Market value
$615.4M
Quote Oct 19
Floor
$10.26
10.6% below price
Resistance
$11.52
0.4% above price
Price vs analyst targets
10 analysts
Lowest target
$30.00Highest target
$60.00
$30.00Highest target
$60.00
- Price $11.47
- Average target $44.71
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 290% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AVTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free